Ad
related to: theophylline therapeutic use in adults with dementia research report
Search results
Results from the WOW.Com Content Network
Theophylline's first clinical use came in 1902 as a diuretic. [35] It took an additional 20 years until it was first reported as an asthma treatment. [ 36 ] The drug was prescribed in a syrup up to the 1970s as Theostat 20 and Theostat 80, and by the early 1980s in a tablet form called Quibron.
GTS-21 (DMXBA or DMBX-anabaseine) is a drug that has been shown to enhance memory and cognitive function.It has been studied for its potential therapeutic uses, particularly in the treatment of neurodegenerative diseases and psychiatric disorders.
Later research found that the combination was no more effective for asthma than theophylline alone but produced more side effects. [9] [1] [12] [7] Combinations of theophylline, ephedrine, and phenobarbital (brand name Tedral among others) have also been widely used to treat asthma.
Dementia A recent study carried out by experts from the University of Nottingham and funded by the National Institute for Health Research (NIHR) has shown there to be an increased risk of up to 50% of patients developing Dementia due to some of these medications and cautions have been advised with their use.
8-Phenyltheophylline (8-phenyl-1,3-dimethylxanthine, 8-PT) is a drug derived from the xanthine family which acts as a potent and selective antagonist for the adenosine receptors A 1 and A 2A, but unlike other xanthine derivatives has virtually no activity as a phosphodiesterase inhibitor.
Older people are more likely to experience drowsiness from antihistamine use than younger people. [1] Continuous and/or cumulative use of anticholinergic medications, including first-generation antihistamines, is associated with higher risk for cognitive decline and dementia in older people. [31] [32]
It has been found to be effective in the treatment of apathy in people with dementia [112] [98] [113] [114] and was reported to reverse escitalopram-associated apathy in a case report. [111] [115] The GPR139 agonist zelatriazin (TAK-041; NBI-1065846) has shown pro-motivational effects in animals.
The Dementia with Lewy Bodies Consortium (DLB Consortium or DLBC) is an international multidisciplinary collaboration of researchers interested in the dementia with Lewy bodies. [1] It first convened in Newcastle upon Tyne, England, in October 1995. [1] Between 1995 and 2005, it issued three DLBC Consensus Reports on dementia with Lewy bodies. [2]
Ad
related to: theophylline therapeutic use in adults with dementia research report